Assistant Editor, OncLive®
Jessica joined the company in August 2019 and is one of the point contacts for the OncLive On Air™ podcast. She is a Rider University alumna and holds a degree in journalism and biology. Prior to joining MJH Life Sciences, she interned with the Ireland-based social media monitoring agency Olytico and served as a copy editor and writer for The Rider News. Email: jhergert@onclive.com
Personalized Medicine Could Be the Key to Bridging Health Disparities in Cancer Care
November 4th 2021Expanding the definition of personalized medicine to include social determinants of health disparities is needed to ensure patients with cancer receive optimal care, said Karen Winkfield, MD, PhD, who added that lessons learned from the COVID-19 pandemic have sparked a new wave of enthusiasm to advocate for change and bridge existing gaps in oncology.
Read More
Genomic Testing Cooperative Seeks to Increase Accessibility to Genomic Profiling Across Cancers
November 2nd 2021Maher Albitar, MD, discusses the unmet needs with genomic testing that served as the impetus to start GTC, the process of becoming a partner with the organization, and the importance of genomic profiling for all patients with cancer.
Read More
Men carrying MSH2 and MSH6 pathogenic variants, which are associated with Lynch syndrome, were found to have a higher incidence of prostate cancer compared with age-matched non-carrier individuals, supporting the value of annual, targeted prostate-specific antigen screening from age 40 to identify men with clinically significant prostate cancer.
Read More
Preventive and Early Intervention Strategies Among Next Steps in cGVHD Management
October 28th 2021As the armamentarium continues expanding for the treatment of patients with chronic graft-vs-host disease, research is ongoing to determine whether earlier integration of novel therapies, such as ruxolitinib, could yield better response rates for patients.
Read More
COVID-19 Vaccination Strategies Should Consider Infection Risks for CAR T-Cell Therapy Recipients
October 28th 2021Although CAR T-cell therapies have demonstrated unprecedented activity in patients with heavily pretreated relapsed/refractory hematologic malignancies, they are marked by a significant risk of infections and may limit the efficacy of COVID-19 vaccines.
Read More
cGVHD Paradigm Gains Systemic Options Beyond Steroids, But Real-World Data Are Required
October 27th 2021Yi-Bin Chen, MD, discusses the nuances of diagnosing patients with cGVHD, the need for biomarkers to inform who is likely to develop the disease, the introduction of ruxolitinib and belumosudil to the paradigm, and future directions with novel strategies in the space.
Read More
Research Underscores the Need for Serological Testing After COVID-19 Vaccination in Multiple Myeloma
October 26th 2021A proportion of patients with multiple myeloma receiving CD38-directed and BCMA-directed therapies had a lack of T-cell responses and an absence of anti–SARS-CoV-2 Spike antibodies following SARS-CoV-2 vaccination, underscoring the need for serological testing after vaccination to identify these patients.
Read More
Toxicity Management Remains Key With Expanding Frontline Treatment Options in Lung Cancer
October 25th 2021Antoinette Wozniak, MD, FACP, FASCO, highlights the importance of monitoring patients with lung cancer for toxicities and significant advances on the horizon that are expected to further expand the lung cancer armamentarium.
Read More
Pevonedistat Plus Ibrutinib Showcases Preliminary Efficacy and Tolerability in CLL and MCL
October 21st 2021The investigational NEDD8-activating enzyme inhibitor pevonedistat in combination with ibrutinib demonstrated high response rates with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.
Read More
Implementable Changes Could Improve QOL With Radiation-Related Mucositis in Head and Neck Cancer
October 20th 2021Anurag Singh, MD, discussed the potential advantage to treating patients with radiation therapy at specific times of day, how the utilization of prophylactic gabapentin has decreased the need for narcotics in managing oral mucositis in patients with head and neck cancer, and the potential use of single-fraction radiation therapy in oncology.
Read More
Trial Launches to Evaluate Novel ADC in Previously Treated HER2+ Breast Cancer
October 19th 2021The phase 2 ACE-Breast03 trial has been launched to evaluate the efficacy and safety of ARX788, an investigational antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer who have progressed on prior HER2-directed therapies.
Read More
Expanding Armamentarium Underscores the Importance of Close Monitoring in Urothelial Cancer
October 12th 2021Evan Y. Yu, MD, provided insight into treatment sequencing for patients with metastatic urothelial carcinoma, considerations for treatment decisions, and emerging therapies in the paradigm.
Read More
Chemotherapy-Free Options Expand the Scope of Treatment in Leukemia and Lymphoma
October 12th 2021Across the paradigms of leukemias and lymphomas, novel therapies—such as BTK inhibitors, PI3K inhibitors, time-limited therapies, and even CAR T-cell therapies—have transformed the treatment of patients and prolonged survival without the need for chemotherapy.
Read More
New Surgical and Systemic Approaches Enable Earlier Intervention in CRC With Liver Metastases
October 8th 2021Shikha Jain, MD, FACP, and Mario Spaggiari, MD, highlight key advancements made in the treatment of patients with colorectal cancer and liver metastases, patient and disease factors to consider for surgical and systemic treatment, and the importance of multidisciplinary care for this population.
Read More
Retroperitoneal Surgical Resection Requires Multipronged Decision Making in Sarcoma
October 8th 2021Retroperitoneal surgery for patients with sarcoma requires nuanced decision making that incorporates technical aspects of resection, as well as patient-related and tumor-related factors, according to a presentation given during the 2021 ESMO Congress.
Read More
Management Strategies Shift Across NSCLC, Small Cell Lung Cancer, and Mesothelioma
October 7th 2021As novel therapies, new treatment strategies, and ongoing clinical trials continue to steer the path forward in lung cancer, treatment patterns for patients with non–small cell lung cancer, small cell lung cancer, and mesothelioma are continuing to evolve.
Read More
Molecular Testing Is Critical With New Targets, Novel Therapies, and Earlier Intervention in NSCLC
October 7th 2021David R. Gandara, highlights key data regarding the earlier integration of targeted therapy in NSCLC, the growing role of molecular testing with tissue and liquid biopsy, and the importance of incorporating a multidisciplinary approach to patient care in the paradigm.
Read More
ctDNA Reduction Is Potentially Predictive of OS Vs RECIST in Metastatic Uveal Melanoma
October 4th 2021A linear correlation between magnitude of circulating tumor DNA reduction and improved overall survival was observed in patients with metastatic uveal melanoma who were treated with tebentafusp, suggesting that ctDNA may be a better surrogate end point for OS compared with RECIST response criteria.
Read More
Molecular Testing and Multidisciplinary Care Is A Necessity in Metastatic NSCLC
October 1st 2021Although adjuvant targeted therapy options are reserved for patients with EGFR-mutated non–small cell lung cancer, molecular testing is a critical step in the treatment of all patients with metastatic disease, where multiple driver mutations are associated with FDA-approved therapeutics.
Read More
Single-Agent and Combo Immunotherapy Garners Mixed Excitement in Gynecologic Cancers
September 30th 2021Immunotherapy is emerging as a preferred second-line treatment option for patients with gynecologic cancers, including endometrial and cervical cancer. Checkpoint inhibitors may also be preferred to chemotherapy in the frontline or adjuvant settings based on improved efficacy.
Read More
Later-Line Therapy in Metastatic CRC Calls for Safety Considerations in Refined Decision Making
September 30th 2021Kanwal P.S. Raghav, MBBS, MD, discussed nuances to treatment selection in mCRC, the significance of the phase 2 ReDOS trial with regorafenib, and how the paradigms for mCRC, HCC, and gastroesophageal cancers have expanded from areas of unmet need to ones with more robust armamentariums.
Read More
Checkpoint Inhibitors Demonstrate Broad Reach in GU Cancers
September 28th 2021Rohit Jain, MD, MPH, discusses the nuances of treatment selection for patients with platinum-eligible vs -ineligible metastatic urothelial carcinoma, the current state of immunotherapy in this disease, and factors to consider during the decision-making process in RCC and mCRPC.
Read More
Prolonged Overall Survival Observed With Oral Decitabine/Cedazuridine in MDS and CMML
September 24th 2021Updated data from the phase 3 ASCERTAIN trial demonstrated that the oral, fixed-duration combination of decitabine and cedazuridine induced a median overall survival of 31.7 months in patients with intermediate- and high-risk myelodysplastic syndrome, including chronic myelomonocytic leukemia.
Read More
Immunotherapy Combos, Novel Agents Hold Promise in Recurrent Ovarian Cancer
September 24th 2021Ritu Salani, MD, MBA, discussed the clinical rationale to evaluate combination strategies with immunotherapy in ovarian cancer, as well as novel agents in clinical development that could further influence the treatment paradigm.
Read More